{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:14:46Z","timestamp":1788952486425,"version":"build-2803163510"},"reference-count":101,"publisher":"Wiley","issue":"14","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2026,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Although there have been significant advances in the management of gynecologic malignancies in recent years, individuals with advanced disease continue to have high rates of recurrence. Strategies to decrease rates of recurrence and increase time to recurrence are urgently needed. Historically, prolonged chemotherapy treatment and consolidation therapy were unsuccessful. However, continuation of maintenance therapy after initial chemotherapy may offer improved progression\u2010free survival (PFS) and overall survival (OS) in select circumstances. In recent years, maintenance agents including VEGF and poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors have improved PFS and sometimes even OS among women with ovarian cancer when used as monotherapy or in combination. PARP inhibitors demonstrate particularly robust results in patients with\n                    <jats:italic>BRCA<\/jats:italic>\n                    \u2010mutated disease or other homologous recombination\u2013deficient cancers. In endometrial and cervical cancers, immune checkpoint inhibitors combined with chemotherapy and used as maintenance thereafter have improved PFS and OS, with particular benefits noted in mismatch repair\u2013deficient endometrial cancer and PD\u2010L1\u2013positive cervical cancer. Beyond currently available therapies, ongoing trials are exploring additional options for maintenance therapy, including antibody\u2013drug conjugates, hormone\u2010directed therapies, and novel targeted therapies such as XPO\u20101 inhibitors. Maintenance therapy can be accompanied by increased toxicity and cost; as such, careful consideration must be made about the relative benefit of any given maintenance strategy weighed against potential impacts on quality of life or financial toxicity. This review focuses on current maintenance therapy practices, emerging areas of research, and challenges in this area of study.\n                  <\/jats:p>","DOI":"10.1002\/cncr.70517","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T17:20:02Z","timestamp":1783099202000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Maintenance therapy in gynecologic malignancies: Current and future state"],"prefix":"10.1002","volume":"132","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-3105-6963","authenticated-orcid":false,"given":"Page C.","family":"Widick","sequence":"first","affiliation":[{"name":"Harvard Medical School  Boston Massachusetts USA"},{"name":"Department of Medical Oncology Dana\u2010Farber Cancer Institute  Boston Massachusetts USA"},{"name":"Department of Medical Oncology Beth Israel Deaconess Medical Center  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9776-7114","authenticated-orcid":false,"given":"Alexi A.","family":"Wright","sequence":"additional","affiliation":[{"name":"Harvard Medical School  Boston Massachusetts USA"},{"name":"Department of Medical Oncology Dana\u2010Farber Cancer Institute  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3888-3972","authenticated-orcid":false,"given":"Joyce F.","family":"Liu","sequence":"additional","affiliation":[{"name":"Harvard Medical School  Boston Massachusetts USA"},{"name":"Department of Medical Oncology Dana\u2010Farber Cancer Institute  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"e_1_2_8_2_1","volume-title":"Global Cancer Observatory","year":"2022"},{"key":"e_1_2_8_3_1","volume-title":"Cancer Statistics Center"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1993.1081"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/0090\u20108258(92)90305\u20103"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1023\/a:1008256431090"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2017.00177"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.gco.0000192995.20040.ff"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2004.22.90140.5006"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2003.11.018"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007414.pub3"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(13)62146\u20107"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djj296"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2005.12.020"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2004.09.016"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.17.8400"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2003.07.013"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.00146"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2009.04.012"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2007.12.0782"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1104390"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.01009"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1103799"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(15)00086\u20108"},{"key":"e_1_2_8_25_1","volume-title":"FDA Approves Bevacizumab in Combination With Chemotherapy for Ovarian Cancer","year":"2018"},{"key":"e_1_2_8_26_1","volume-title":"Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer","year":"2019"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.42.0505"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2015.08.004"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(17)30279\u20106"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(20)30637\u20109"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1810858"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01549"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1910962"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2241"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.2283"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.01003"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.10.007"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1911361"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.05.005"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(17)30469\u20102"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00073-5"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1611310"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2025.03.018"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.12.018"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102629"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(17)32440\u20106"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115584"},{"key":"e_1_2_8_48_1","volume-title":"FDA Approves Genentech\u2019s Avastin\u00ae (Bevacizumab) Plus Chemotherapy for a Specific Type of Advanced Ovarian Cancer","year":"2016"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.2147\/ott.s499226"},{"key":"e_1_2_8_50_1","volume-title":"FDA Approved Olaparib (LYNPARZA, AstraZeneca Pharmaceuticals LP) for the Maintenance Treatment of Adult Patients With Deleterious or Suspected Deleterious Germline or Somatic BRCA\u2010Mutated (gBRCAm or sBRCAm) Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Who Are in Complete or Partial Response to First\u2010Line Platinum\u2010Based","year":"2018"},{"key":"e_1_2_8_51_1","volume-title":"NDA\/BLA Clinical and Statistical Review","year":"2025"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2269"},{"key":"e_1_2_8_53_1","volume-title":"Supplemental New Drug Application Letter (Olaparib plus Bevacizumab)","year":"2020"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2022.05.020"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2025.06.014"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1105535"},{"key":"e_1_2_8_57_1","volume-title":"FDA Approves Olaparib Tablets for Maintenance Treatment in Ovarian Cancer","year":"2017"},{"key":"e_1_2_8_58_1","volume-title":"FDA Approves Niraparib for Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","year":"2017"},{"key":"e_1_2_8_59_1","volume-title":"Dear Health Care Provider Letter (Niraparib)","year":"2022"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2016.01.022"},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.71.0632"},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2026.02.023"},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2023.41.16_suppl.tps5627"},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.10.828"},{"key":"e_1_2_8_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.06.011"},{"key":"e_1_2_8_66_1","volume-title":"FDA Online Label Repository","year":"2026"},{"key":"e_1_2_8_67_1","volume-title":"AACR Cancer Progress Report","year":"2023"},{"key":"e_1_2_8_68_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.02105"},{"key":"e_1_2_8_69_1","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1097\u20100215(19970304)70:5<499::aid\u2010ijc1>3.0.co;2\u2010t"},{"key":"e_1_2_8_70_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2216334"},{"key":"e_1_2_8_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.05.546"},{"key":"e_1_2_8_72_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2302312"},{"key":"e_1_2_8_73_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010025\u201003566\u20101"},{"key":"e_1_2_8_74_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.02132"},{"key":"e_1_2_8_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2024.07.092"},{"key":"e_1_2_8_76_1","volume-title":"Imfinzi (Durvalumab)","year":"2018"},{"key":"e_1_2_8_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(24)00334\u20106"},{"key":"e_1_2_8_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.09.051"},{"key":"e_1_2_8_79_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2012.00062"},{"key":"e_1_2_8_80_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.76.5966"},{"key":"e_1_2_8_81_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.ccr\u201020\u20100953"},{"key":"e_1_2_8_82_1","volume-title":"Evaluation of Carboplatin\/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer","year":"2023"},{"key":"e_1_2_8_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2018.05.018"},{"key":"e_1_2_8_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2019.10.013"},{"key":"e_1_2_8_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2021.01.025"},{"key":"e_1_2_8_86_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10585\u2010007\u20109087\u20105"},{"key":"e_1_2_8_87_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.02906"},{"key":"e_1_2_8_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(23)00479\u20105"},{"key":"e_1_2_8_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(24)00317\u20109"},{"key":"e_1_2_8_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(24)01808\u20107"},{"key":"e_1_2_8_91_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2112435"},{"key":"e_1_2_8_92_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.00914"},{"key":"e_1_2_8_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(23)02405\u20104"},{"key":"e_1_2_8_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105140"},{"key":"e_1_2_8_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(24)02135\u20104"},{"key":"e_1_2_8_96_1","volume-title":"FDA Approves Pembrolizumab With Chemoradiotherapy for FIGO 2014 Stage III\u2013IVA Cervical Cancer","year":"2024"},{"key":"e_1_2_8_97_1","volume-title":"FDA Approves Merck's KEYTRUDA (pembrolizumab) Plus Chemotherapy, With or Without Bevacizumab, as Treatment for Patients with Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD\u2010L1 (CPS \u2265 1)","year":"2021"},{"key":"e_1_2_8_98_1","volume-title":"NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer","year":"2025"},{"key":"e_1_2_8_99_1","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2026.37.e46"},{"key":"e_1_2_8_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2024.11.002"},{"key":"e_1_2_8_101_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.28620"},{"key":"e_1_2_8_102_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2025.101761"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.70517","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cncr.70517","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.70517","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:39:01Z","timestamp":1788950341000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.70517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":101,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2026,7,15]]}},"alternative-id":["10.1002\/cncr.70517"],"URL":"https:\/\/doi.org\/10.1002\/cncr.70517","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"2026-05-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70517"}}